Banner
    Rosetta Genomics And Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary And Metastatic Tumors In
    By Anna Ohlden | July 9th 2008 08:33 AM | Print | E-mail | Track Comments

    REHOVOT, Israel and JERSEY CITY, New Jersey, July 9 /PRNewswire/ --

    - Study Demonstrates Differentiation of Primary Tumors From Metastases in the Brain With Accuracy Near 90%

    - Identifying Whether a Brain Malignancy is a Primary Tumor or a Metastasis is a Recurring Challenge for Pathologists Using Current Technologies

    - Accurately Differentiating Primary From Metastatic Tumors is Critical for Optimal Treatment

    Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today that the results of a study conducted by its scientists and collaborators and describing the use of microRNAs in accurately differentiating primary from metastatic tumors of the brain, have been published online in the peer-reviewed journal Brain Pathology. The findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify primary tumors in patients with brain cancers.

    "This latest study conducted by our scientists, as well as our previously published Nature Biotechnology paper, are further validation of microRNAs' vast potential to act as accurate biomarkers in various cancers," noted Dr. Dalia Cohen, Chief Scientific Officer of Rosetta Genomics. "We are continually optimizing our microRNA platform technologies to leverage them in the development of a wide range of microRNA-based diagnostics, primarily for cancer."

    The study results, published in Brain Pathology, describe the development and validation of microRNA expression profiles for characterization of brain malignancies. Rosetta Genomics' scientists measured microRNA expression in RNA extracted from hundreds of formalin-fixed, paraffin-embedded (FFPE) samples of brain primary tumors and various other tissues, as well as 60 samples of metastatic brain tumors. Two microRNAs, miR-92b and miR-9/9*, were found to be significantly over-expressed in brain primary tumors, and may represent potential biomarkers for the identification of brain primary tumors.

    The paper demonstrates, based on a blinded test set, that the overall sensitivity and specificity of this classifier are approximately 90%.

    The paper, "MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors" is now available on Brain Pathology's website on http://www3.interscience.wiley.com/journal/118497402/home.

    About microRNAs

    MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. MicroRNAs have been shown to have different expression profiles in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

    About Rosetta Genomics

    Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs . Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working to develop a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by CLIA-certified laboratories in the United States in 2008.

    Forward-Looking Statement Disclaimer

    Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the potential of microRNAs to act as effective biomarkers for a diagnostic test designed to identify primary tumors in patients with brain cancers, the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, and the timing of launch of the first diagnostic tests applying Rosetta's microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

    Contact: Media& Investors Ron Kamienchick T: +1-646- 509-1893 E: investors@rosettagenomics.com

    Contact: Media& Investors, Ron Kamienchick, T: +1-646-509-1893, E: investors@rosettagenomics.com